B. Cancilla

发表

Abstract 1907: Wnt pathway antagonist OMP-54F28 (FZD8-Fc) inhibits tumor growth and reduces tumor-initiating cell frequency in patient-derived hepatocellular carcinoma and ovarian cancer xenograft models

M. Fischer, J. Lewicki, A. Gurney, 2014 .

Abstract A30: Predictive and pharmacodynamic biomarkers of vantictumab (OMP-18R5; anti-Frizzled) in non-small cell lung cancer

M. Fischer, J. Lewicki, T. Hoey, 2015 .

Localization of Activin b A-, b B-, and b C-Subunits in Human Prostate and Evidence for Formation of New Activin Heterodimers of b C-Subunit *

A. Mason, J. Pedersen, G. Risbridger, 2000 .

Localization of activin beta(A)-, beta(B)-, and beta(C)-subunits in humanprostate and evidence for formation of new activin heterodimers of beta(C)-subunit.

A. Mason, J. Pedersen, G. Risbridger, 2000, The Journal of clinical endocrinology and metabolism.

Light-microscopic immunolocalization of fibroblast growth factor-1 and -2 in adult rat kidney

J. Bertram, V. Nurcombe, D. Alcorn, 1996, Cell and Tissue Research.

Immunolocalization of fibroblast growth factor‐1 and ‐2 in the embryonic rat kidney

J. Bertram, V. Nurcombe, D. Alcorn, 1996 .

Discrete cell- and stage-specific localisation of fibroblast growth factors and receptor expression during testis development.

G. Risbridger, B. Cancilla, A. Davies, 2000, The Journal of endocrinology.

Fibroblast growth factor receptors and their ligands in the adult rat kidney.

J. Bertram, G. Risbridger, B. Cancilla, 2001, Kidney international.

Differential localization of fibroblast growth factor receptor-1, -2, -3, and -4 in fetal, immature, and adult rat testes.

G. Risbridger, B. Cancilla, 1998, Biology of reproduction.

Correlative tumor molecular profiling and plasma biomarker analysis in a phase II study of XL184 in patients with progressive or recurrent glioblastoma multiforme (GBM).

M. Prados, P. Wen, J. D. de Groot, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development of the Zebrafish Lymphatic System Requires Vegfc Signaling

H. Wolburg, J. Peterson-Maduro, E. Gjini, 2006, Current Biology.

Abstract B269: Pharmacodynamic and correlative biomarker analyses in clinical trials of XL184, an oral, potent inhibitor of MET, VEGFR2, and RET

J. Li, Lora Zhao, V. Vysotskaia, 2009 .

Abstract 1549: Development and validation of a biomarker for prospective selection of Notch1 activation in patients with certain advanced solid tumors in a first-in-human phase1 study of the cancer stem cell targeting antibody OMP-52M51 (anti-Notch1)

J. Lewicki, T. Hoey, S. Anderson, 2015 .

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

Yongchang Shi, Yu-Chien Chou, K. Yamaguchi, 2011, Molecular Cancer Therapeutics.

Differential localization of inhibin subunit proteins in the ovine testis during fetal gonadal development.

G. Risbridger, N. Groome, K. McNatty, 1999, Endocrinology.

Discovery and characterization of an inhibitor of glucosylceramide synthase.

K. Ogilvie, J. Nuss, S. Richards, 2012, Journal of medicinal chemistry.

In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.

F. Yakes, A. Joly, Lora Zhao, 2013, Thyroid : official journal of the American Thyroid Association.

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

M. Fischer, J. Lewicki, A. Gurney, 2015, Clinical Cancer Research.

Intratumoral heterogeneity generated by Notch signaling promotes small cell lung cancer

K. Garcia, M. Fischer, J. Sage, 2017, Nature.

RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations

M. Fischer, T. Hoey, F. Cattaruzza, 2017, Scientific Reports.

Evidence that estrogens directly alter androgen-regulated prostate development.

G. Prins, K. Thayer, G. Risbridger, 2000, Endocrinology.

WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death

M. Fischer, J. Lewicki, A. Gurney, 2017, Science Advances.

Role of activins in the male reproductive tract.

G. Risbridger, B. Cancilla, 2000, Reviews of reproduction.

Regulation of prostate branching morphogenesis by activin A and follistatin.

Hong Wang, G. Risbridger, G. Cunha, 2001, Developmental biology.

89 POSTER Evaluation of peripheral blood cells and hair as surrogate tissues for clinical trial pharmacodynamic assessment of XL147 and XL765, inhibitors of the PI3K signaling pathway

A. Laird, A. Sillman, Felix Chu, 2008 .

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

G. Shapiro, A. Zhu, E. Heath, 2010, Clinical Cancer Research.

Abstract 4652: Effects of anti-DLL4 treatment on non-small cell lung cancer (NSCLC) human xenograft tumors

M. Fischer, J. Lewicki, A. Gurney, 2016 .

Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647

F. Yakes, A. Joly, J. Martini, 2007, Clinical Cancer Research.

Expression and localization of fibroblast growth factors and fibroblast growth factor receptors in the developing rat kidney.

J. Bertram, J. Bertram, B. Cancilla, 1999, Kidney international.

Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types.

M. Fischer, J. Lewicki, A. Gurney, 2016, Cancer research.

Abstract 3129: Predictive biomarker identification for response to vantictumab (OMP-18R5; anti-Frizzled) using primary patient-derived human pancreatic tumor xenografts

M. Fischer, J. Lewicki, A. Gurney, 2016 .

Preclinical Development Cabozantinib ( XL 184 ) , a Novel MET and VEGFR 2 Inhibitor , Simultaneously Suppresses Metastasis , Angiogenesis , and Tumor Growth

K. Yamaguchi, J. Lesch, F. Yakes, 2011 .

Abstract 404: Development of a RSPO3 CLIA-validated assay as a predictive biomarker for response to anti-RSPO3 antibody treatment in patients with solid tumors

M. Fischer, J. Lewicki, A. Gurney, 2016 .

Abstract 3728: Anti-Notch1 antibody (OMP-52M51) impedes tumor growth and cancer stem cell frequency (CSC) in a chemo-refractory breast cancer xenograft model with an activating Notch1 mutation and screening for activated Notch1 across multiple solid tumor types.

L. Esserman, J. Lewicki, A. Gurney, 2013 .

Abstract 255: Dual targeting of Delta-like ligand 4 (DLL4) and programmed death 1(PD1) inhibits tumor growth and generates enhanced long-term immunological memory

J. Lewicki, A. Gurney, T. Hoey, 2015 .

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

K. Yamaguchi, F. Yakes, A. Joly, 2011, Molecular Cancer Therapeutics.

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

M. Fischer, J. Lewicki, A. Gurney, 2015, Clinical Cancer Research.

Therapeutic targeting of tumor-derived R-spondin attenuates β-catenin signaling and tumorigenesis in multiple cancer types

J. Lewicki, A. Gurney, T. Hoey, 2015 .

A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma.

David C. Smith, H. Hurwitz, C. Britten, 2010 .